ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine (PROMISE 2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02974153
Recruitment Status : Completed
First Posted : November 28, 2016
Last Update Posted : September 19, 2018
Sponsor:
Information provided by (Responsible Party):
Alder Biopharmaceuticals, Inc.

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Completed
  Actual Primary Completion Date : November 2017
  Actual Study Completion Date : April 2018
  Certification/Extension First Submitted : September 17, 2018